| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000020589 |
| Receipt No. | R000023769 |
| Official scientific title of the study | Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism |
| Date of disclosure of the study information | 2017/09/30 |
| Last modified on | 2017/03/05 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism | |
| Title of the study (Brief title) | Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism | |
| Region |
|
|
| Condition | ||
| Condition | Japanese adult without clinical and radiographic evidence of knee osteoarthritis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effect of N-acetyl-glucosamine on the cartilage metabolism and safety |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | change in C2C/PIICP (weeks 16 during the intervention)
chnge in C2C/PIICP (weeks 8 and 12 during the intervention, weeks 8 after intervention) |
| Key secondary outcomes | change in C2C (weeks 8, 12 and 16 during the intervention, weeks 8 after intervention)
change in PIICP (weeks 8, 12 and 16 during the intervention, weeks 8 after intervention) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | N-acetyl-glucosamine (500 mg/day, weeks 16 during the intervention) | |
| Interventions/Control_2 | Placebo (500 mg/day, weeks 16 during the intervention) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Japanese adult (aged 40-74) without clinical and radiographic evidence of knee osteoarthritis | |||
| Key exclusion criteria | 1.Subjects with gout or rheumatoid arthritis
2.Subjects with surgical treatment of joint performed or its necessity 3.Subjects with routine use of health foods which are good for bone or joint 4.Subjects with the presence of any clinically significant conditions judged by the medical investigator to preclude the subject's participation in the study |
|||
| Target sample size | 120 | |||
| Research contact person | |
| Name of lead principal investigator | Mihoko Kurokawa |
| Organization | Q' SAI CO.,LTD. |
| Division name | Research Department |
| Address | 1-7-16 Kusagae, Chuo-ku, Fukuoka-shi, JAPAN |
| TEL | 092-724-0855 |
| kurokawa@kyusai.co.jp | |
| Public contact | |
| Name of contact person | Takashi Nakagawa |
| Organization | TTC Co.,Ltd. |
| Division name | Clinical Research Planning Department |
| Address | 1-20-2, Ebisunishi, Shibuya-ku, Tokyo |
| TEL | 03-5459-5329 |
| Homepage URL | |
| t.nakagawa@ttc-tokyo.co.jp | |
| Sponsor | |
| Institute | Q' SAI CO.,LTD |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Q' SAI CO.,LTD |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023769 |